Cost‐Related Medication Behaviors for Patients With and Without Systemic Autoimmune Rheumatic Diseases
Authors' conclusion
In this large diverse cohort, patients with versus without SARDs had more self-reported cost-related medication behaviors, and those who reported medication unaffordability received fewer disease-modifying drugs and had more emergency room visits.
Study context
- Population
- All of Us (version 7) nationwide diverse adult cohort, United States
- Participants
- 3,997 vs 73,990
- Exposure
- Patients with systemic autoimmune rheumatic diseases (SARDs) vs participants without SARDs
- SARDsn = 3,997
- Without SARDsn = 73,990reference
- Outcome
- Cost-related medication behaviors (unaffordability of prescription medicines, cost-related medication nonadherence, cost-reducing strategies)
Methodological detailsnationwide diverse adult cohort with linked electronic health records, questionnaires, logistic regression
- Nationwide diverse adult cohort with linked electronic health records
- Questionnaires
- Logistic regression
Main finding
As reported in the abstract
Adjusted odds (unaffordability of prescription medicines)
1.56
95% CI 1.43–1.70
SARDs
Adjusted odds (cost-related medication nonadherence)
1.43
95% CI 1.31–1.56
SARDs
Adjusted odds (using cost-reducing strategies)
1.23
95% CI 1.14–1.32
SARDs
Observational data: associations, not effects.
Further findings
Treatment received among SARDs patients reporting unaffordability
- Less likely to receive a disease-modifying drug
- 16.5% (95% CI 0.70-0.99)
- More likely to receive GC
- 18.1% (95% CI 0.99-1.42)
ED visits associated with unaffordability of prescription medicines
- Increased odds of 1–2 ED visits per year
- 1.27 (95% CI 1.03-1.57)
- Increased odds of ≥3 ED visits per year
- 1.38 (95% CI 0.96-1.99)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →